WeDoctor

elsewhere's corpus doesn't carry a full profile of WeDoctor itself — the company mostly appears in portfolio roundups and partner news flashes rather than in-depth coverage. What the material does establish: it's a digital healthcare company whose investor base includes 5Y Capital (which backed it early from a TMT angle, per a 5Y piece ), Qiming Venture Partners, and Hongshan — the latter describing it as one of its earliest healthcare bets in an 暗涌Waves look back at Hongshan's 17 years in the sector . Recent activity glimpses: in January 2023 it was among the first in mainland China to open Hong Kong appointment bookings for AstraZeneca's Evusheld antibody treatment, per 5Y Capital's monthly , and in April 2024 it signed strategic and cloud-platform cooperation agreements with Tencent . For founding story and business model detail, elsewhere doesn't yet have direct coverage — note that the similarly-named 微脉 (WeiMai) in the results below is a different company.